Biohit Oyj Targets East Asia-Prevalent Form Of Stomach Cancer
This article was originally published in PharmAsia News
Executive Summary
Finland drug maker Biohit Oyj is eyeing China's drug market for what CEO Semi Korpela says could be a good fit for its Acetium (l-cysteine) treatment for a genetic form of stomach cancer prevalent in Asia.